Creating engineered cell therapies for cancer and autoimmune diseases
Design-driven engineering of robust mammalian sense-and-respond functions: from parts to programs
This study is exploring new ways to create personalized cell treatments that could help people with cancer and autoimmune diseases by making the cells smarter so they can remember and fight these conditions better, aiming to offer quicker and more effective options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11081816 on NIH RePORTER |
What this research studies
This research focuses on developing advanced engineered cell therapies that can effectively treat a variety of conditions, including cancer and autoimmune diseases. By leveraging natural genetic mechanisms, the project aims to create customized therapies that can provide long-lasting effects. The approach involves building genetic programs that allow cells to remember and respond to specific conditions, enhancing their therapeutic potential. Patients may benefit from faster and more effective treatment options as the research seeks to streamline the evaluation of these therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with cancer or autoimmune diseases who are seeking advanced treatment options.
Not a fit: Patients with conditions unrelated to cancer or autoimmune diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative and effective treatments for cancer and autoimmune diseases, improving patient outcomes.
How similar studies have performed: Other research has shown promising results in the field of engineered cell therapies, indicating a strong potential for success with similar approaches.
Where this research is happening
Chicago, UNITED STATES
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Leonard, Joshua Nathaniel — Northwestern University
- Study coordinator: Leonard, Joshua Nathaniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.